Novocure announced that the company will present three abstracts studying Tumor Treating Fields (TTFields) in pancreatic cancer at the European Society for Medical Oncology 19thWorld Congress on Gastrointestinal Cancer on June 28 through July 1 in Barcelona. Among the highlights is an abstract that will outline the trial design for PANOVA-3, Novocure’s phase 3 pivotal study of TTFields with gemcitabine and nab-paclitaxel as a front-line treatment of locally advanced pancreatic cancer. PANOVA-3, a prospective, randomized trial, will include 600 patients with unresectable locally advanced pancreatic cancer. Patients should have an Eastern Cooperative Oncology Group (ECOG)score of 0-2 and no prior progression or treatment. Experimental-arm patients will use a TTFields delivery system tuned to 150 kHZ for at least 18 hours a day until the disease progresses. Follow up, including a CT scan of the chest and abdomen, will be performed every eight weeks. Patients who progress will be followed monthly for survival. The primary endpoint is overall survival. The secondary endpoints are progression-free survival, objective response rate, rate of resectability, quality of life and toxicity. The following abstracts will be presented at the European Society for Medical Oncology 19th World Congress on Gastrointestinal Cancer: PANOVA-2: A phase 2 study of TTFields (150 kHz) concomitant with standard chemotherapy for front-line therapy of advanced pancreatic adenocarcinoma – Updated efficacy results; M. Benavides, C. Guillen, F. Rivera, J. Gallego, J.A. Lopez-Martin, M. Küng; June 29; abstract: #315. PANOVA-3: A phase 3 study of TTFields with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (LAPC); Uri Weinberg, Ori Farber, Moshe Giladi, Ze'ev Bomzon, Eilon Kirson; June 29; abstract: P-230. A simulation-based study on the distribution of TTFields in the body when treating pancreatic cancer; Cornelia Wenger, Ofir Yesharim, Ariel Naveh, Hadas Hershkovich, Uri Weinberg and Ze'ev Bomzon; June 29; abstract: #335. TTFields are not approved for the treatment of pancreatic cancer by the U.S. Food and Drug Administration. The safety and effectiveness of TTFields therapy for pancreatic cancer has not been established.